The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

Prior treatment

• Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.) or intravenous medication;

Other illness

• Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);
• Patients with any other severe and/or uncontrolled disease;
• Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;
• Patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers；

• Patients pathologically diagnosed as non-small cell lung cancer, and was early stage（AJCC 8th）;
• Patients aged between 18 -80 years; with expected survival time\>3 months.
• Patients with normal organ function within 30 days prior to treatment, the following criteria are met:
  • blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥80×10e9/L; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min;